Trial Profile
A Phase II Clinical Trial of the PARP Inhibitor Talazoparib in BRCA1 and BRCA2 Wild Type Patients With Advanced Triple Negative Breast Cancer and Homologous Recombination Deficiency or Advanced HER2 Negative Breast Cancer or Other Solid Tumors With a Mutation in Homologous Recombination Pathway Genes
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 Feb 2023
Price :
$35
*
At a glance
- Drugs Talazoparib (Primary)
- Indications Advanced breast cancer; HER2 negative breast cancer; Solid tumours; Triple negative breast cancer
- Focus Proof of concept; Therapeutic Use
- 16 Feb 2023 Status changed from active, no longer recruiting to completed.
- 16 Nov 2022 Planned End Date changed from 1 Dec 2023 to 1 Dec 2022.
- 16 Nov 2022 Status changed from recruiting to active, no longer recruiting.